Wireless Solution Delivers Cost Savings and Real-time Access to Key Patient Data
ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to market its AM3® GSM devices in respiratory clinical trials. The AM3 GSM device provides a robust and reliable wireless option for clinical trial patients to communicate key spirometry data during the clinical development of new respiratory treatments.
Upon completion of a patient session, the AM3 GSM automatically sends and receives data using secure SMS text messages utilizing the global GSM M2M network. Because GSM M2M offers wide international roaming capabilities, this solution offers a very cost-effective method for routine data transfers. An analog modem solution via ERT’s VIAConnect® is also available for patients without wireless coverage.
ERT’s AM3 device measures and saves all relevant expiratory flow-volume parameters, such as PEF and FEV1, and records events, medication, and symptoms — including standardized assessments like the ACQ for asthma trials and EXACT-PRO for COPD — delivering a complete electronic diary for home monitoring.
Achim Schuelke, Executive Vice President and Respiratory Product Line Executive at ERT stated, “Now with the availability of AM3 GSM, these important respiratory data can be simply and cost-effectively transferred from a patient’s home which allows near real-time access to patient data for investigators and sponsors, enabling better patient monitoring and, ultimately, better care.”
With nearly 80,000 AM3 devices used solely in worldwide clinical trials since 2009, ERT has the proven respiratory experience that sponsors can trust. To learn more about ERT’s centralized respiratory services and for more information on ERT’s enhancements to the AM3 family of devices, visit www.ert.com/respiratory.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.